Research underway to treat rare brain cancers.

Michael Salgaller, Michael Pollack, Michele Newton

Abstract read

In one paragraph

Article in MedNous, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael SalgallerMichael Salgaller leads the Invention Development and Marketing Unit of the National Cancer Institute's (NCI's) Technology Transfer Centre (TTC) within the National Institutes of Health. Michael Pollack is a unit supervisor within the NCI TTC. Michele Newton is a communications specialist for the same unit within the NCI.

Michael PollackMichael Salgaller leads the Invention Development and Marketing Unit of the National Cancer Institute's (NCI's) Technology Transfer Centre (TTC) within the National Institutes of Health. Michael Pollack is a unit supervisor within the NCI TTC. Michele Newton is a communications specialist for the same unit within the NCI.

Michele NewtonMichael Salgaller leads the Invention Development and Marketing Unit of the National Cancer Institute's (NCI's) Technology Transfer Centre (TTC) within the National Institutes of Health. Michael Pollack is a unit supervisor within the NCI TTC. Michele Newton is a communications specialist for the same unit within the NCI.

Funding

Intramural NIH HHS Z99 CA999999

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42667002

PMCPMC13524166

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.